Functional CAR-T Benchmarking
StimCytes synthetic target cell mimics carry BCMA, CD19 or CD20 at a fixed antigen density, so CAR-T activation and cytotoxicity readouts reflect your product rather than the target material you happened to source that month.
What a CAR-T potency assay measures
A CAR-T potency assay quantifies whether an engineered T cell product does what it was designed to do: recognize its target antigen, activate, and kill. Common readouts include target cell cytotoxicity, activation marker expression such as CD69 and CD25, cytokine release, and the proportion of CAR-positive cells in the product.
Every one of those readouts is measured against a target. If the target changes between runs, the potency number changes with it, and you have no way to tell whether the shift came from your product or your reagent. Antigen density on the target cell drives activation strength directly, which makes it the variable worth controlling first.
Benchmark against a target that doesn't move
Fixed antigen density
Antigen density drives activation strength. Tumor cell lines drift with passage number, including antigen expression levels, so a line that expressed a marker at one density in year one will not match it in year three. A manufactured target holds its specification.
No donor sourcing
Primary cells vary between donors, do not scale, and bring consent and chain-of-custody considerations that get harder as a program moves toward commercial supply.
36-month shelf life, no cold chain
Non-biohazardous and shipped without dry ice. In-house cryopreserved CAR-T controls have been validated with a post-thaw working window of roughly six hours, which constrains how you schedule a run.
Built for assay transfer
One unchanging reference across sites, operators and instruments. Cross-site comparability studies get easier when both labs are measuring against the same material.
Shop Functional CAR‑T Benchmarking
Showing 3 products
Powered by Bioz
StimCytes™ BCMA are precision engineered synthetic cell mimics designed to support CAR‑T potency assessment through targeted BCMA specific activation, cytokine release and biomarker driven assay development. Each kit enables baseline, enhanced and negative activation profiles of BCMA directed CAR‑T cells during antigen engagement. Unlike cell controls, StimCytes™ BCMA provides consistent antigen expression and reproducible activation characteristics that remove the variability associated with donor derived materials. These lyophilized synthetic cells feature selected biomarkers that support stable potency evaluation and streamlined assay optimization across experiments and platforms. The kit includes a baseline activation mimic, an enhanced activation mimic with enhancers and a non activating negative control to establish clear functional benchmarks. The StimCytes™ BCMA product is part of an early release program with specifications subject to refinement as additional validation is completed. These products are intended for research use only and are not suitable for diagnostic or therapeutic procedures. They are safe to use in any environment, contain no biohazardous material and require no special disposal. ResourcesTechnical Data Sheet
StimCytes™ CD19
Slingshot Bio Reagent
StimCytes™ CD19 are precision engineered synthetic cell mimics designed to support CAR‑T potency assessment through targeted CD19 specific activation, cytokine release and biomarker driven assay development. Each kit enables baseline, enhanced and negative activation profiles of CD19 directed CAR‑T cells during antigen engagement. Unlike cell controls, StimCytes™CD19 provides consistent antigen expression and reproducible activation characteristics that remove the variability associated with donor derived materials. These lyophilized synthetic cells feature selected biomarkers that support stable potency evaluation and streamlined assay optimization across experiments and platforms. The kit includes a high activation mimic with enhancers, a baseline activation mimic and a non activating negative control to establish clear functional benchmarks. StimCytes™ CD19 are intended for research use only and are not suitable for diagnostic or therapeutic procedures. These products are safe to use in any environment, contain no biohazardous material and require no special disposal. (FKA: TruCytes® Potency CD19) More information: Poster:Cell Mimics as High Precision Controls For CGT Analytics and Potency Assays Application Note:Cell Mimics as a Robust Quality Control Platform for Reliable CAR-T Potency Assays ResourcesTechnical Data Sheet
StimCytes™ CD20 are precision engineered synthetic cell mimics designed to support CAR‑T potency assessment through targeted CD20 specific activation, cytokine release and biomarker driven assay development. Each kit enables baseline, enhanced and negative activation profiles of CD20 directed CAR‑T cells during antigen engagement. Unlike cell controls, StimCytes™ CD20 provides consistent antigen expression and reproducible activation characteristics that remove the variability associated with donor derived materials. These lyophilized synthetic cells feature selected biomarkers that support stable potency evaluation and streamlined assay optimization across experiments and platforms. The kit includes a CD20 activation mimic with enhancers and a non activating negative control to establish clear functional benchmarks. The StimCytes™ CD20 product is part of an early release program with specifications subject to refinement as additional validation is completed. These products are intended for research use only and are not suitable for diagnostic or therapeutic procedures. They are safe to use in any environment, contain no biohazardous material and require no special disposal. ResourcesTechnical Data Sheet
A repeatable benchmarking workflow
- 1
Establish your reference
Select StimCytes targets matched to the antigen your CAR-T assay measures: BCMA, CD19 or CD20.
- 2
Benchmark every run
Co-culture with the fixed-density target and read cytotoxicity or activation alongside your samples to anchor the assay.
- 3
Compare with confidence
Track potency readouts against a target that holds its specification across lots, operators, sites, and time.
Benchmarks Your QC Needs
Protocols, case studies, and standards for reproducible CAR-T characterization.
Novel EGFR+ CD3+ Cell Mimics for Validating CAR-T Cell Enumeration by Flow Cytometry
Reducing Time and Costs in Car-T Development with Precision-Engineered Cell Mimics
High-Parameter Cytometry Simplified: SpectraComp® & ViaComp® Workflows for Compensation and Unmixing
How Potency Assay Strategy Can Accelerate Cell Therapy Development
CYTO 2026
CAR-T potency assay FAQs
What is a CAR-T potency assay?
A test that measures whether a CAR-T product performs its intended biological function: recognizing its target antigen, activating, and killing target cells. Potency is a critical quality attribute and a required release test for licensed products.
Why use synthetic target cells instead of a tumor cell line?
Cell lines drift with passage number, so antigen density shifts over a program's lifetime. Since potency is expressed relative to that target, drift in the target propagates into the potency number. They also need continuous culture, banking and QC.
Do these controls require cold-chain shipping or biosafety handling?
No. StimCytes are non-biohazardous synthetic material with a 36-month shelf life and ship without dry ice. No pathogen screening or donor consent documentation.
References
- 1.Cai Y, Prochazkova M, Jiang C, et al. Establishment and validation of in-house cryopreserved CAR/TCR-T cell flow cytometry quality control. J Transl Med. 2021;19(1):523. doi:10.1186/s12967-021-03193-7
Ready to standardize your CAR-T potency assay?
Talk to our team about matching StimCytes targets to your potency, cytotoxicity and release workflows.